Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Abeona Therapeutics (Nasdaq: ABEO) has announced the granting of equity awards to eight new non-executive employees. The Compensation Committee approved these inducement grants on January 31, 2024, consisting of a total of 13,000 restricted shares of common stock. The equity awards were granted in compliance with Nasdaq Listing Rule 5635(c)(4).
The vesting schedule for these restricted stock awards is structured over three years, with one-third of the shares vesting annually on each grant date anniversary. Full vesting will occur on the third anniversary of the Grant Date, contingent upon continued employment with Abeona.
Abeona Therapeutics (Nasdaq: ABEO) ha annunciato l'assegnazione di premi azionari a otto nuovi dipendenti non esecutivi. Il Comitato per la Remunerazione ha approvato queste concessioni di indennità il 31 gennaio 2024, consistenti in un totale di 13.000 azioni ordinarie vincolate. I premi azionari sono stati concessi in conformità con Nasdaq Listing Rule 5635(c)(4).
Il piano di maturazione per queste azioni vincolate è strutturato su tre anni, con un terzo delle azioni che matura annualmente all'anniversario della data di concessione. La maturazione completa avverrà al terzo anniversario della Data di Concessione, a condizione di continuare l'impiego presso Abeona.
Abeona Therapeutics (Nasdaq: ABEO) ha anunciado la concesión de premios de capital a ocho nuevos empleados no ejecutivos. El Comité de Compensación aprobó estos premios de inducción el 31 de enero de 2024, consistiendo en un total de 13,000 acciones restringidas de acciones ordinarias. Los premios de capital se otorgaron en cumplimiento de Nasdaq Listing Rule 5635(c)(4).
El cronograma de adquisición para estas acciones restringidas está estructurado en tres años, con un tercio de las acciones adquiriéndose anualmente en cada aniversario de la fecha de concesión. La adquisición total ocurrirá en el tercer aniversario de la Fecha de Concesión, sujeta a la continuación del empleo en Abeona.
Abeona Therapeutics (Nasdaq: ABEO)는 여덟 명의 신규 비상임 직원에게 주식 보상을 부여했다고 발표했습니다. 보상위원회는 2024년 1월 31일 이 유인 보상을 승인했으며, 총 13,000주의 제한된 보통주가 포함됩니다. 주식 보상은 Nasdaq Listing Rule 5635(c)(4)에 따라 부여되었습니다.
이 제한된 주식 보상을 위한 배분 일정은 3년 동안 구조화되어 있으며, 매년 보상일 기념일에 각각 1/3의 주식이 배분됩니다. 전체 배분은 보상일의 세 번째 기념일에 발생하며, Abeona에서 계속 근무하는 것을 조건으로 합니다.
Abeona Therapeutics (Nasdaq: ABEO) a annoncé l'octroi de récompenses en capital à huit nouveaux employés non exécutifs. Le Comité de Rémunération a approuvé ces attributions d'incitation le 31 janvier 2024, consistant en un total de 13 000 actions ordinaires restreintes. Les récompenses en capital ont été accordées conformément à Nasdaq Listing Rule 5635(c)(4).
Le calendrier d'acquisition pour ces actions restreintes est structuré sur trois ans, avec un tiers des actions acquises chaque année à l'anniversaire de la date d'octroi. L'acquisition complète se produira au troisième anniversaire de la Date d'Octroi, sous réserve de la poursuite de l'emploi chez Abeona.
Abeona Therapeutics (Nasdaq: ABEO) hat die Gewährung von Aktienoptionen an acht neue nicht-executive Mitarbeiter bekannt gegeben. Der Verg Ausschuss genehmigte diese Anreizvergaben am 31. Januar 2024, die aus insgesamt 13.000 eingeschränkten Stammaktien bestehen. Die Aktienoptionen wurden gemäß Nasdaq Listing Rule 5635(c)(4) vergeben.
Der Vesting-Plan für diese eingeschränkten Aktienoptionen ist über drei Jahre strukturiert, wobei ein Drittel der Aktien jährlich am Jahrestag des Gewährungsdatums fällig wird. Die vollständige Vesting erfolgt am dritten Jahrestag des Gewährungsdatums, abhängig von der Fortsetzung der Beschäftigung bei Abeona.
- Company strengthens employee retention through equity-based compensation
- Structured vesting schedule promotes long-term employee commitment
- Potential dilution of existing shareholders through new share issuance
CLEVELAND, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).
On January 31, 2024, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to eight individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 13,000 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards will vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee will be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Prademagene zamikeracel (pz-cel) is Abeona’s investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa. The Company’s fully integrated cell and gene therapy cGMP manufacturing facility served as the manufacturing site for pz-cel used in its Phase 3 VIITAL™ trial, and is capable of supporting commercial production of pz-cel upon FDA approval. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. For more information, visit www.abeonatherapeutics.com.
Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “anticipate,” “expect,” “intend,” “potential,” and similar words and expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to, the timing and outcome of the FDA’s review of our BLA resubmission for pz-cel; the FDA’s grant of a Priority Review Voucher upon pz-cel approval; continued interest in our rare disease portfolio; our ability to enroll patients in clinical trials; the outcome of future meetings with the FDA or other regulatory agencies, including those relating to preclinical programs; the ability to achieve or obtain necessary regulatory approvals; the impact of any changes in the financial markets and global economic conditions; risks associated with data analysis and reporting; and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.
FAQ
How many restricted shares did Abeona Therapeutics (ABEO) grant in its January 2024 inducement awards?
What is the vesting schedule for ABEO's January 2024 inducement stock awards?
How many new employees received ABEO's January 2024 equity inducement grants?
Under which Nasdaq rule did ABEO issue its January 2024 inducement grants?
